<DOC>
	<DOCNO>NCT00311415</DOCNO>
	<brief_summary>Immunogenicity , Safety , Tolerability Ability Prime Memory Meningococcal C Conjugate Vaccine healthy child</brief_summary>
	<brief_title>Immunogenicity , Safety , Tolerability Ability Prime Memory Meningococcal C Conjugate Vaccine Healthy Children</brief_title>
	<detailed_description>The aim study investigate immunogenicity offer MenCC vaccine administer different schedule different year life : 2 dos first year life give 2 month apart ( 2 4 month age ) , booster second year life , 1 dose first year life ( 2 6 month age ) , booster second year life , 1 dose second year life .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy infant know hypersensitivity vaccine component significant acute chronic infection previously ascertain suspected disease cause N. meningitidis previous household contact individual positive culture N. meningitidis serogroup C</criteria>
	<gender>All</gender>
	<minimum_age>7 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Prevention Meningococcal Meningitis</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>conjugate</keyword>
	<keyword>immunology</keyword>
	<keyword>infant</keyword>
	<keyword>antibody persistence</keyword>
</DOC>